Medpace Q4 revenue up 18.8% to $308.6M; full year revenue +23.4%; Board approves $300M buyback increase

Medpace Holdings, Inc.

2021-FY EPS reported $4.81 revenue$1,142,377,000

Q4 2021 GAAP net income $50.0M ($1.32 EPS) vs $50.9M ($1.35 EPS) prior year; net income margin 16.2%.
Full year 2021 GAAP net income $181.8M ($4.81 EPS) vs $145.4M ($3.84 EPS); net income margin 15.9%.
Net new business awards Q4 $458.7M (book-to-bill 1.49x), up 27.9% YoY; backlog $1,997.1M (+29.5%).
EBITDA Q4 $61.4M (19.9% margin) vs $60.2M (23.2%) prior year; full year EBITDA $223.1M (19.5% margin).
Board increased stock repurchase program by $300 million; program has no set expiration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.